Prostate cancer — all decisions

The Board denied the Veteran's claim for an effective date prior to August 29, 2023, for a 40 percent disability rating for residuals of prostate cancer.

The Board granted an initial compensable disability evaluation of 20 percent for voiding dysfunction associated with prostate cancer, while withdrawing the appeals for ischemic heart disease and diabetes mellitus type II.

The Veteran has withdrawn the appeal for all issues, and the Board does not have jurisdiction to review the appeal.

The Board granted service connection for prostate cancer, diabetes mellitus II, tumor on pituitary gland, and hypertension under the PACT Act. The skin condition and special monthly compensation claims were remanded.

The Board granted service connection for prostate cancer and conditions secondary to it, including erectile dysfunction, hypertension, ischemic stroke, urge incontinence, upper and lower extremity neuropathies, and a heart disability. The claims for other conditions were remanded for further development.

The Board denied the veteran's claims for increased ratings and effective dates for his service-connected prostate cancer and type II diabetes mellitus, finding that the evidence did not support a higher evaluation or an earlier effective date.

The Board granted service connection for prostate cancer and urinary incontinence, both of which are presumptively related to the Veteran's exposure to herbicide agents while serving near the Korean demilitarized zone.

The Board remands the claims for further development, specifically to determine if the Veteran was exposed to perfluoroalkyl and polyfluoroalkyl substances (PFAS) during service.

The Board remands the claims for service connection for prostate cancer and skin cancer to correct a pre-decisional duty to assist error.

The Board remands the matter for a VA examination to address the nature and etiology of the Veteran's prostate cancer, considering environmental exposures during service in the Gulf War.

The Board granted service connection for prostate cancer and skin cancer, finding the evidence to be at least in relative equipoise.

The Board remands the Veteran's claim for service connection for prostate cancer to obtain a medical examination and opinion regarding the nature and etiology of the condition, specifically considering in-service exposure to contaminated water at Camp Lejeune.

The Board granted service connection for prostate cancer with incontinence and impotence, effective August 10, 2022.

The Board remands the claim for service connection for prostate cancer to obtain a new medical opinion, as the previous opinions were found inadequate.

The Board dismissed the veteran's claims for earlier effective dates and denied an increased rating for erectile dysfunction, while granting a reduced rating for prostate cancer residuals.

The Board denied service connection for Parkinson's disease, prostate cancer, and hypertension as there was no evidence of in-service herbicide exposure or a nexus to service.

The Board remands the case to obtain an opinion on whether the Veteran's prostate cancer is related to his in-service exposure to asbestos, particulate matter, and/or firefighting chemicals.

The veteran withdrew his appeal for an increased rating of prostate cancer with urinary frequency and incontinence, effective April 1, 2025.

The Board remands the claims for service connection for diabetes mellitus and prostate cancer to correct a duty to assist error related to verifying the Veteran's exposure to herbicide agents while stationed in Korea.

The Board granted service connection for prostate cancer due to herbicide exposure based on the Veteran's service in Vietnam.